News >

Lenvatinib HCC Data Published as FDA Considers Approval

Jason Harris
Published: Tuesday, Feb 20, 2018

Masatoshi Kudo, MD

Masatoshi Kudo, MD
Lenvatinib (Lenvima) was noninferior for overall survival (OS) while improving progression-free survival (PFS) compared with sorafenib (Nexavar) for the frontline treatment of patients with unresectable hepatocellular carcinoma (HCC), according to findings from the phase III REFLECT trial now published online in the Lancet.1

“Real-life experience and further data will inform us about the effect of lenvatinib in the treatment landscape. Although it is great to have a new drug in the repertoire, only time will tell if lenvatinib has changed real-life systemic treatment for hepatocellular carcinoma patients.”

References

  1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial [published online February 9, 2018]. Lancet. doi:10.1016/S0140-6736(18)30207-1.
  2. Reig M, Bruix J. Lenvatinib: can a non-inferiority trial change clinical practice? [published online February 9, 2018]. Lancet. doi: 10.1016/S0140-6736(18)30208-3.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x